Algotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a product for distributing medical images and clinical data over the Internet and intranets. Shipments have already begun via a worldwide
Algotec of Raanana, Israel, has received Food and Drug Administration 510(k) clearance for its MediSurf software, a product for distributing medical images and clinical data over the Internet and intranets. Shipments have already begun via a worldwide OEM relationship with Elscint.
MediSurf users employ a standard World Wide Web browser and applets based on the Java programming language developed by Sun Microsystems. The browser is used to access the MediSurf DICOM 3.0-compliant server, which is linked to both clinical image and data sources. There is no need for installation of additional hardware or software at end-user sites, according to the company.
Algotec debuted MediSurf at last year's Radiological Society of North America meeting (SCAN Special Report 12/96). In addition to three beta sites in the U.S., Canada, and Germany, MediSurf has been installed at nine other institutions. Two MediSurf packages have been installed in the U.S.
Initially, Algotec will market MediSurf in the U.S. through OEMs. In a few months, however, the firm will sell MediSurf via regional distributors as well as through direct sales in some cases, said Kobi Margolin, Algotec marketing manager. Because the company expects OEMs to contribute most of MediSurf's sales, Algotec is actively looking for OEM relationships in addition to the Elscint agreement, Margolin said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.